TeamDrive
RUS
Leonid Melamed

Leonid Melamed

Founding Partner, Chairman of The Board of Directors

Телефоны:

+7 495 545-39-12

Send message

​Leonid has almost 30 years of management experience at large companies in various market sectors.

Leonid – one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Leonid Melamed is the co-founder and Chairman of the Board of Directors of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is NovaMedica LLC. At the present time Leonid is a member of the Board of Directors of RusnanoMedInvest and from 2012 to 2017 he was a member of the Board of NovaMedica.

Leonid also is the co-founder and member of the Board of Directors of Doctor Ryadom (network of medical clinics), which among the first in Russia began to provide telemedicine services to its patients.

Earlier Leonid was the President and Chairman of the Management Board and member of the Board of Directors of Sistema JFSC (from 2008 to 2011). From 2006 to 2008, Leonid ran the telecommunications company Mobile TeleSystems (MTS OJSC) as President and Chairman of the Management Board. For 15 years from 1991 to 2006 Leonid participated in the creation and development of ROSNO insurance company. In 2003 he was the head of ROSNO as CEO and Chairman of the Management Board.

His personal “portfolio” includes Russneft OJSC as Chairman of the Board of Directors (2010-2012) and VTB OJSC as a member of the Supervisory Board (2012-2013).

Currently, Leonid is a member of the Government Expert Council of the Russian Federation, which was established to involve the business community in the preparation and implementation of the Government’s decisions.

Leonid graduated with honours from I.M. Sechenov Moscow Medical Academy and in 2006 became a Doctor of Medical Sciences.

Media Center

  • 22 February 2018

    Korea pools patient data to enable digital health schemes

    South Korea is consolidating hospital medical data into a single 10 million-patient repository. The goal is to use Korea’s established medical IT system to build a resource that supports digital health initiatives and the development of new drugs and devices.

  • 21 February 2018

    Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

    Pfizer hasn't gained much market share with Inflectra, its biosimilar of Johnson & Johnson's Remicade, since its U.S. launch back in 2016. The company's CEO Ian Read recently said Inflectra is picking up increased commercial coverage, but an analyst figures the biosimilar's challenges aren't likely to let up this year. 

  • 20 February 2018

    Using stem cells to generate an immune attack against cancer

    Induced pluripotent stem cells (iPSCs) have the power to transform into any cell in the body, making them a prime candidate for regenerative medicine. But can they also teach the immune system to recognize and attack cancer?

  • 20 February 2018

    Russians develop advanced multiple myeloma drug candidate

    Hemopharm, a Russian biotech company, is developing a drug candidate that might help multiple myeloma patients. The new Hemopharm solution is expected to evolve to be such a drug. No direct competition has been reported so far in the global pharmaceutical market. The drug candidate is a humanized antibody with purportedly outstanding anti-tumor activity and low toxicity with proven in vivo efficacy.

Read more